Novel strategies for the pharmacological management of type 2 diabetes

被引：23
作者：
Nourparvar, A
Bulotta, A
Di Mario, U
Perfetti, R
机构：
[1] Cedars Sinai Med Ctr, Div Endocrinol & Metab, Los Angeles, CA 90048 USA
[2] Univ Roma La Sapienza, Dept Clin Sci, Rome, Italy
来源：
TRENDS IN PHARMACOLOGICAL SCIENCES | 2004年 / 25卷 / 02期
关键词：
D O I：
10.1016/j.tips.2003.12.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Type 2 diabetes is characterized by high concentrations of glucose in the blood, which is caused by decreased secretion of insulin from the pancreas and decreased insulin action. This condition is prevalent worldwide and is associated with morbidity and mortality secondary to complications such as myocardial infarction, stroke and end-stage renal disease. The importance of tight control of blood glucose in either preventing or delaying the progression of complications is recognized. Currently, there are many therapeutic options to treat hyperglycemia in type 2 diabetes. However, tight control is difficult to achieve and is often associated with side-effects. Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. In this article, we review new molecules that are promising candidates for the future management of diabetes, focusing on their mechanism of action, efficacy, safety profile and potential benefits compared with pharmacological agents that are available currently.
引用
收藏
页码：86 / 91
页数：6
相关论文
共 60 条
[51]   Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure [J].
Shen, K ;
Keng, YF ;
Wu, L ;
Guo, XL ;
Lawrence, DS ;
Zhang, ZY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (50) :47311-47319
[52]   A double-masked placebo-controlled trial assessing effects of various doses of BTS 67 582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients [J].
Skillman, CA ;
Raskin, P .
DIABETES CARE, 1997, 20 (04) :591-596
[53]   Development of oral insulin: progress and current status [J].
Still, JG .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2002, 18 :S29-S37
[54]  
Tobin JF, 2002, DIABETES, V51, pA116
[55]   Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [J].
Turner, RC ;
Holman, RR ;
Cull, CA ;
Stratton, IM ;
Matthews, DR ;
Frighi, V ;
Manley, SE ;
Neil, A ;
McElroy, K ;
Wright, D ;
Kohner, E ;
Fox, C ;
Hadden, D ;
Mehta, Z ;
Smith, A ;
Nugent, Z ;
Peto, R ;
Adlel, AI ;
Mann, JI ;
Bassett, PA ;
Oakes, SF ;
Dornan, TL ;
Aldington, S ;
Lipinski, H ;
Collum, R ;
Harrison, K ;
MacIntyre, C ;
Skinner, S ;
Mortemore, A ;
Nelson, D ;
Cockley, S ;
Levien, S ;
Bodsworth, L ;
Willox, R ;
Biggs, T ;
Dove, S ;
Beattie, E ;
Gradwell, M ;
Staples, S ;
Lam, R ;
Taylor, F ;
Leung, L ;
Carter, RD ;
Brownlee, SM ;
Fisher, KE ;
Islam, K ;
Jelfs, R ;
Williams, PA ;
Williams, FA ;
Sutton, PJ .
LANCET, 1998, 352 (9131) :837-853
[56]   Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities [J].
Ukkola, O ;
Santaniemi, M .
JOURNAL OF INTERNAL MEDICINE, 2002, 251 (06) :467-475
[57]   Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555 [J].
Upton, R ;
Widdowson, PS ;
Ishii, S ;
Tanaka, H ;
Williams, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1998, 125 (08) :1708-1714
[58]   Early clinical development of pharmaceuticals for type 2 diabetes mellitus: From preclinical models to human investigation [J].
Wagner, JA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (12) :5362-5366
[59]   A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes [J].
Whitehouse, F ;
Kruger, DF ;
Fineman, M ;
Shen, L ;
Ruggles, JA ;
Maggs, DG ;
Weyer, C ;
Kolterman, OG .
DIABETES CARE, 2002, 25 (04) :724-730
[60]  
Zdravkovic M, 2002, DIABETES, V51, pA117
123456